Position in DTIL
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$7,441,117
+$1,966,577 QoQ
Shares Held
946,707
-4.9% QoQ
Ownership
3.43%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
#8
of 95 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in DTIL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Driehaus Capital Management LLC holds $3,602,052,293 across 59 Biotechnology names. DTIL ranks #48 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | DFTX |
Definium Therapeutics, Inc.
|
6,845,276 | $322,001,783 | |
| 2 | PRAX |
Praxis Precision Medicines, Inc.
|
959,048 | $321,079,679 | |
| 3 | XENE |
Xenon Pharmaceuticals Inc.
|
4,418,557 | $266,704,100 | |
| 4 | SYRE |
Spyre Therapeutics, Inc.
|
2,799,166 | $248,509,957 | |
| 5 | CRNX |
Crinetics Pharmaceuticals, Inc.
|
6,463,551 | $241,866,078 | |
| 6 | APGE |
Apogee Therapeutics, Inc.
|
1,740,101 | $230,963,605 | |
| 7 | EWTX |
Edgewise Therapeutics, Inc.
|
4,728,623 | $192,123,952 | |
| 8 | SEPN |
Septerna, Inc.
|
4,433,058 | $148,463,112 |
All Filings in DTIL
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $7,441,117 | 946,707 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $5,474,540 | 995,371 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $3,276,832 | 787,700 | Shares | Sole | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||